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ABSTRACT 
The assessment of overall homogeneity of time-to-event curves is a key element in 
survival analysis in biomedical research. The currently commonly used testing methods, 
e.g. log-rank test, Wilcoxon test, and Kolmogorov–Smirnov test, may have a significant 
loss of statistical testing power under certain circumstances. In this thesis we replicate a 
testing method (Lin & Xu, 2009) that is robust for the comparison of the overall 
homogeneity of survival curves based on the absolute difference of the area under the 
survival curves using normal approximation by Greenwood’s formula, and propose a new 
weight component to their test statistic. The weight component is added to Lin and Xu’s 
test statistic to better fit the data at hand (i.e. emphasizing more weight on earlier data).  
Monte Carlo simulations are conducted to investigate the performance of the new testing 
method compared against the log-rank, Wilcoxon, Kolmogorov–Smirnov, and Lin & 
Xu’s tests under a variety of circumstances. The proposed new weighted method has 
robust performance compared to the common test statistics, with greater power to detect 
the overall differences than the log-rank, Wilcoxon, Kolmogorov–Smirnov, and Lin & 
Xu’s (2009) tests in many scenarios resulting from the simulations. Furthermore, the 
applicability of the new testing approach is illustrated in a real data example from a 
Leukemia analysis trial. 
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CHAPTER 1 
INTRODUCTION 
1.1. INTRODUCTION 
Survival analysis techniques are typically used in medicine, biology, public health, 
clinical trials, and epidemiology.  The unique characteristic of survival data is the 
existence of censoring. That is, some subjects may experience the event of interest, while 
other subjects may not.  Not experiencing the event may be due to the study period 
ending, loss to follow up, or a subject’s withdrawal from the study.    This is also known 
as right-censored data.  An event of interest can be defined as death, disease occurrence, 
disease recurrence, or recovery; any of which is referred to as a “failure”. Traditional 
statistical models, such as multiple linear regression, cannot handle censoring directly, 
which is why survival models are specifically designed to manage data with censored 
observations. If censoring is ignored in a study, the results will tend to lead to 
underestimation of the survival probability.    
The basic objectives in survival analysis include estimating and interpreting survival 
probabilities, comparing survival probabilities between groups, and assessing the possible 
risk factors that are related to survival probability.  In this thesis, we focus on methods 
comparing survival curves between two groups. These methods are evaluated based on 
the power of the method.  Section 1.2 introduces specific survival notation and 
definitions that will be used throughout this thesis.  Section 1.3 introduces data of 
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Leukemia patients, and the Kaplan Meier estimation method. Section 1.4 outlines the 
organization of the thesis.  
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1.2 DEFINITION AND NOTATION 
The survival function gives the probability that a person survives longer than some 
specified time, t. The survival probability is a decreasing function from 1 to 0, which 
means that at the beginning of the study, all patients are alive and have not yet 
experienced the event (Klein 1997).  The survival function, S(t), can be written as: 
 
S(t) = P(T > t) 
 
where T is defined as a random variable for an individual’s survival time, and t represents 
any specific value of interest for the random variable T (Klein 1997). 
The hazard function gives the instantaneous potential per unit time for the event to occur, 
given that the individual has survived up to time t (Klein 1997).  The Hazard function can 
be written as: 
h(t) = lim∆ 	
  ∆|∆  
 
where h(t) equals the limit, as ∆t approaches zero of a probability statement about 
survival, divided by ∆t, where ∆t  denotes a small interval of time.   
The Kaplan Meier estimator is a nonparametric method that incorporates 
censoring for estimating survival probabilities (Klein 1997). This is the estimate of the 
unconditional probability of surviving beyond time t.  The Kaplan Meier estimator is 
used to compare the survival information between different groups.  For a sample of size 
n, let ti represent distinct event times in the sample, where  t1 ≤  t2≤…≤ tk 
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The Kaplan Meier estimator, given below, is the estimated survival probability for any 
particular one of the t time periods. The Kaplan–Meier estimate does not change between 
events, nor at times when only censorings occur. It drops only at times when a failure has 
been observed. 
The Kaplan-Meier estimator of the survival function is given by: 
 
	= ∏ 	1  
  
 
Where ni is the number of subjects at risk at the beginning of time period ti, and mi is the 
number of subjects who had the event occur during time period ti.. The ratio / is the 
overall proportion in the population failing at time ti, (i.e., the hazard). One minus this 
ratio gives the probability of the hazard at time ti.  
From Greenwood’s formula, the variance of the Kaplan Meier estimate of the 
survival function is written as: 
 !"# $%# 	& '  %	( )

	  |

 
 
The variance allows us to obtain confidence intervals for all ordered failure times. This 
gives us a point wise confidence interval for the survival probability, Skm(t). Brookmeyer 
and Crowly (1982) constructed the confidence interval for the median survival time based 
on the confidence interval for Skm(t).  The methodology is generalized to construct the 
confidence interval for the 100p percentile based on a g-transformed confidence interval 
for S(t).  The transformation that was used in this situation was the Loglog 
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transformation, where g(x) = log(-log(x)).  This is also referred to as the log cumulative 
hazard transformation since it applies to the logarithmic function to the cumulative 
hazard function (Brookmeyer and Crowly 1982).  This is interpreted as the true Skm(t) at 
time t will be within the interval for 95% of experiments conducted. 
 
1.3. EXAMPLE OF LEUKEMIA DATA 
The dataset we will use as our example of real data analysis was a study designed 
to test the ability of a therapy to prolong the duration of remission in acute leukemia 
patients (Freireich et al. 1963). Ninety-two patients under age 20 entered the study and 
were accepted for analysis.  Of those 92 patients, 62 had complete or partial remissions 
(Freireich et al. 1963). Patients in remission were randomly assigned to maintenance 
therapy with either 6-Mercaptopurine treatment applied or a placebo. A sequential 
experimental design was used to analyze remission times while the study was in progress, 
which resulted in the study being stopped after analysis of the remission times of 21 pairs 
of patients.  Those 21 pairs of patients (42 individual patients) were used to construct the 
dataset for our study.  The dataset described in Table 1.1 consists of 42 patients (≤ 20 
years) with leukemia, divided evenly into two groups: the first group had a 6-
Mercaptopurine treatment applied (X1=1), and group 2 was designated as a placebo 
(X1=0). The values given for each group consist of time in weeks a patient is in remission, 
up to the point of the patient’s either going out of remission (event of interest) or being 
censored (ti).  An individual was censored (δi=0) if they remained in remission until the 
end of the study, was lost to follow-up, or withdrew before the end of the study, else δi=1.  
We assume that censoring is noninformative, meaning that each subject’s censoring time 
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is statistically independent of their failure time.  Gender is indicated by X2, where 
0=males and 1=females.  According to this dataset, the proportion of patients who 
received treatment (6-Mercaptopurine) that were censored is 12 out of 21 (9 out of 21 
patients had the event occur), while 0 out of 21 patients receiving the placebo were 
censored (21 out of 21 had the event occur). The proportion of females who were 
censored is 6 out of 22 (16 out of 22 had the event occur), while the proportion of males 
who were censored is 6 out of 20 (14 out of 20 had the event occur). 
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TABLE 1.1. Description of Leukemia Data remission time in weeks (Freireich et al., 
Blood, 1963) 
ti δi X1 X2 
1 1 1 1 
1 1 1 1 
2 1 1 1 
2 1 1 1 
3 1 1 1 
4 1 1 1 
4 1 1 1 
5 1 1 1 
5 1 1 0 
6 0 2 0 
6 1 2 0 
6 1 2 1 
6 1 2 0 
7 1 2 0 
8 1 1 0 
8 1 1 0 
8 1 1 0 
8 1 1 1 
9 0 2 0 
10 0 2 0 
10 1 2 0 
11 0 2 0 
11 1 1 0 
11 1 1 0 
12 1 1 0 
12 1 1 0 
13 1 2 0 
15 1 1 0 
16 1 2 1 
17 0 2 0 
17 1 1 0 
19 0 2 0 
20 0 2 1 
22 1 2 1 
22 1 1 0 
23 1 1 1 
23 1 1 1 
25 0 1 1 
32 0 1 1 
32 0 1 1 
34 0 1 1 
35 0 1 1 
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For our first scenario, we consider the comparison of the treatment (Group 1) and placebo 
(Group 2) subjects.  We test the null hypothesis that the patient groups have the same 
survival distribution against the alternative that the survival distributions are different. 
The null hypotheses are given by: 
 
Ho: S1(t) = S2(t) -OR- Ho: h1(t) = h2(t) 
Ha: S1(t) ≠ S2(t)  Ha: h1(t) ≠ h2(t). 
 
 The survival and the logarithm of cumulative hazard function plots for the group 
comparison are shown below in Figures 1.1 and 1.2.  
 9 
 
 
 
FIGURE 1.1. Kaplan Meier survival curves for Group 1 (treatment) and Group 2 (placebo)
 10 
 
 
 
FIGURE 1.2 Logarithm of Cumulative Hazard Function curves for Group 1 (treatment) 
and Group 2 (placebo) 
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Figure 1.1 and 1.2 plots the two treatment groups by survival probability versus the 
survival time and display proportional hazards. From these figures, we can conclude that 
patients who receive the 6-Mercaptopurine treatment have a longer survival rate than the 
patients in the placebo group.  Also, based on the fact that there is little overlap between 
the confidence bands in Figure 1.1, we can conclude that there may be a difference in 
survival probability between the two treatment groups.  Various tests have been proposed 
for testing statistical differences in survival between categorical covariates, such as the 
long rank test and Wilcoxon test.  These tests will be explained in further detail in chapter 
2.   
For our second example, we use the same dataset but stratify by gender rather 
than by group.  Figure 1.3 and 1.4 represent the Kaplan Meier survival function and the 
logarithm of cumulative hazard function curves for males and females.
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FIGURE 1.3 Kaplan Meier survival curves for males and females for males (0) and 
females (1) 
. 
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FIGURE 1.4 Cumulative Hazard Function curves for males (0) and females (1) 
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The survival probability and cumulative hazard function plots suggests that we cannot 
adjust for sex in the PH model.  From Figure 1.4, we can see that while adjusting for 
gender, plotting the survival probability versus the survival time result in intersecting 
hazards. From Figure 1.3, it appears that male patients begin with a larger survival 
probability, but over time (after about 12 weeks) women appear to have a higher survival 
probability.  Also, the confidence interval bands overlap each other substantially, which 
further supports our claim that it isn’t clear there is a difference in survival between 
males and females.   
 
1.4. OUTLINE OF THESIS 
In Chapter 2, we describe at length the log rank test, the weighted log rank test 
(i.e. Wilcoxon), the Kolmogorov-Smirnov test, Lin and Xu’s proposed test, and our 
proposed weighted version of Lin and Xu’s test. For each statistical procedure 
introduced, we will be testing the same hypotheses; as stated in the example prior, we test 
the null hypothesis that the patient groups have the same survival distribution against the 
alternative that the survival distributions are different. The null hypotheses are given by: 
 
Ho: S1(t) = S2(t) -OR- Ho: h1(t) = h2(t) 
Ha: S1(t) ≠ S2(t)  Ha: h1(t) ≠ h2(t). 
 
  
   
Where Si(t) denotes the survival function where i = 1 or 2 representing the treatment and 
placebo group, respectively.  hi (t) denotes the hazard function where i = 1 or 2 
representing the treatment and placebo group, respectively.  Chapter 3 presents a 
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comprehensive simulation study and describes the simulation design of the weighted Lin 
and Xu’s test statistic under different situations at length.  Chapter 4 evaluates the 
performances of the weighted Lin and Xu’s test statistic and draws conclusions based on 
the results.  The weighted Lin and Xu’s test statistic is applied to the Leukemia dataset in 
Chapter 5. Finally, conclusions and potential future work are summarized in Chapter 6.
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CHAPTER 2 
TEST STATISTICS 
Survival analysis includes a wide variety of methods for analyzing the timing of events 
and comparing survival functions. Throughout this chapter we will discuss the following 
test procedures: the log rank, the Wilcoxon test, the Kolmogorov-Smirnov test, Lin and 
Xu’s proposed test statistic, and our extended version of Lin and Xu’s test statistic. 
2.1. LOG RANK TEST STATISTIC 
The log rank test (Peto R. and Peto J. 1972) is a procedure used to compare the 
survival distributions of two samples. It is a nonparametric test and appropriate to use 
with right censored data (Peto 1972).  The test is sometimes called the Mantel–Cox test, 
named after Nathan Mantel and David Cox (Mantel 1967). The log rank test statistic has 
a distribution that is approximately chi square in large samples (Klein 1997). According 
to Peto (1972), the log-rank test statistic is calculated by obtaining each distinct event 
time, and comparing the hazard rates between the two groups, conditional on the number 
at risk in the groups (Klein 1997). 
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The log-rank test statistic is given by:  
 
*+,-( = 	./01/
2
345	./01/ ~ *	6
(
, 
where789  :9; is sum of the observed minus expected counts over all failure times for 
one of the two groups (Klein 1997). Let j= 0 or 1 indicate the control and treatment 
group, respectively. When j=0, let ti0 be the event time of the ith patient in the control 
group, and δi0 be the censoring indicator (δi0 = 0) of the ith patient in the control group, 
where i = 1, … ,m0, where m0 indicates the last distinct event time in the control group. 
When j=1 and m=1, let ti1 be the event time of the ith patient in the treatment group, and 
δi1 be the censoring indicator  (δi1 = 0) of the ith patient in the treatment group, where i = 
1, … ,m1, where m1 indicates the last distinct event time in the treatment group. 789  :9; 
is given by the formula: 
 
789  :9; ' ∑ 	9  =9# ,??4+@5AABC6 = ∑ 	9# ,??4+@5AABC6  - 
∑ 	=9# ,??4+@5AABC6 , 
 
Where 9 denotes the total number of events in group j at failure time ti, and =9 
indicates the expected total number of events in group j at failure time ti.  
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If H0 is true, =9 can be obtained by the following formula: 
 
=9 = /6( * (6 D (), 
 
where 9is defined by the number of subjects at risk at time , separated by group j.  
The expected cell counts must be computed for both groups. 
The variance of the difference between observed and expected values can be obtained by 
the following formula (Klein 1997): 
 
 !"	89  :9 =∑ E2	E2	E20E02	E22	E2069  
 
An approximation to the log rank statistic can be calculated using observed and expected 
values for each group without having to compute the variance formula given above.  The 
approximate formula sums over each group being compared the square of the observed 
minus expected value divided by the expected value. The approximate formula is given 
by: 
*4FF5,G( =	./01/
2
1/  ~ *	6
(
 
 
Where Oj is the number of observed events for group j and Ej is the number of expected 
events for group j. For a two-sided test with significance level α, the null hypothesis is 
rejected if *+,-( >*	6,60I( . The log rank test is will be optimal test when the 
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underlying hazard rates are proportional to each other. (X. Lin, Q. Xu, 2010). This test 
statistic has been implemented in most statistical softwares, such as, SAS and R, for easy 
use in practice.  For example, in our study, we implemented PROC LIFETEST in SAS to 
obtain the log rank test statistics and used the statistical software program, R, by using 
the R package Survival, and the command “logrank(Surv(time, status))”.  
 
2.2. GENERALIZED WILCOXON TEST STATISITC 
An additional test statistic for detecting statistical differences between survival 
curves is the generalized Wilcoxon test. This is a variation of the log rank test that applies 
a different weight at the JK failure time (R. Peto and J. Peto 1972).  While the log rank 
test gives equal weight to early and late failures, the Wilcoxon test statistic gives more 
weight to earlier failure times.  In other words, the Wilcoxon test places more emphasis 
on the information at the beginning of the survival curve where the number at risk is large 
allowing early failures to receive more weight than later failures.  An example of when 
one might choose to use the Wilcoxon test would be when we are interested in 
investigating whether a treatment is most effective in the earlier phases of administration 
and tends to be less effective over time.  Therefore, this test statistic is considered more 
powerful than the log rank test in detecting early survival differences (Klein 1997). The 
Wilcoxon test statistic has high power when the failure times are lognormally distributed, 
with equal variance in both groups but a different mean (Klein 1997).  
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The Wilcoxon Test Statistic is given by: 
 
*L+M,G,( = 	∑ N	OP	QPR0
SPTE UPR2
345	∑ N	OP7QPR0U/;VTE
  ,   where, w() = 9 
 
Note:  if w(ti) = 1 then this formula reduces to the log rank test. 
At a significance level α, the null hypothesis is rejected if *L+M,G,( >*	6,60I( .  
While the log rank and Wilcoxon are the two tests that are used most frequently, there are 
several other test statistics with a variety of weight settings that will be introduced later in 
this chapter.   These tests will lack power if the survival curves are not proportional 
(Schoenfeld 1981).  However, that does not necessarily mean that the tests are invalid. 
This test statistic has been implemented in most statistical software, such as SAS and R, 
for easy use in practice.  For example, in our study, we implemented PROC LIFETEST 
in SAS to obtain the Wilcoxon test statistics and used the statistical software program, R, 
using the Survival function, and the command “Wilcoxon.test()”. 
 
2.3. KOLMOGOROV-SMIRNOV TEST STATISTIC 
A method that can be used when the underlying PH assumption is not met is the 
Kolmogorov-Smirnov (KS) test statistic (Massey 1951).  The KS-test is suitable for this 
“purpose so that it robustly works in the condition where the hazard functions h1(t) and 
h2(t) cross over through time t” (Massey 1951). This test statistic has been known to have 
greater power than the log-rank and Wilcoxon tests when survival curves are not 
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proportional. However, it is not guaranteed to have more power when the survival curves 
cross.  
 
The Kolmogorov-Smirnov test is based on the following equation. 
 
D[0,τ] = WXY

τ|Ŵ6	  Ŵ(	| 
 
Where sup represents a supremum of a set that gives the smallest real number that is 
greater than or equal to every number in the set, and D represents the largest absolute 
vertical deviation (Massey 1951). [ denotes the last time point by which the areas under 
the survival curves can be calculated for both groups based on the data available. 
|Ŵ6	  Ŵ(	| represents the absolute difference between survival estimates for group 1 
and group 2.  The Kolmogorov-Smirnov test has the advantage of making no assumption 
about the distribution of the data.  It is a non-parametric and distribution free test 
statistics. The hypothesis regarding the distributional form is rejected if the test statistic, 
D, is greater than the critical value obtained from a table. There are several variations of 
these tables in the literature that use somewhat different scalings for the K-S test statistic 
and critical regions (Massey 1951). These alternative formulations should be equivalent, 
but it is necessary to ensure that the test statistic is calculated in a way that is consistent 
with how the critical values were tabulated.  For our study, this test statistic has been 
implemented using R package Surv2Sample, and the command “surv2.ks”.   
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2.4. LIN &XU’S TEST STATISTIC 
Xun Lin and Qiang Xu (2009) proposed a new testing method that is robust for 
the comparison of the overall homogeneity of survival curves.  They based this test 
statistic on the absolute difference of the area under the survival curves using a normal 
approximation based on the Kaplan Meier Estimator.  Their objective with this test 
statistic was to be able to use it for all-purpose situations whether the hazards are 
proportional to each other or not. Their new testing method “not only considers the 
difference in Kaplan Meier estimates between the groups at the actual event time points, 
it also takes into consideration the length of time intervals to better capture the 
differences” (2009).  Some notation that needs to be introduced for this test statistic are as 
follows.  The estimated survival probabilities used for this test statistic are from three 
sources: the control group, the treatment group, and the pooled data set of both groups.  
The notation used in chapter 1 for the Kaplan Meier estimator is consistent with the 
Kaplan Meier estimator for Lin and Xu’s test statistic, given below. The survival 
distribution for each group at time t, Sj(t), can be estimated by the Kaplan-Meier 
estimator 9	, where  
9	= ∏ 	1  //|
  
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The observed absolute difference of the areas under the two survival curves is defined 
below 
∆ = \ ]6	  (	]^_  = ∑ ]6	  (	]	6  |
  
 
where [ is the last time point by which the areas under the survival curves can be 
calculated for both groups based on the data available (Lin and Xu 2009).   In detail,  [ = 
minj(Xj(Nj)) if the last time points in the two groups are both censored, where X=min(ti,δi) 
assuming δi is independent of ti.and where Nj denotes the sample size in group j. For 
example, two Kaplan–Meier curves are both open at the right tails; [  = maxj(Xj(Nj)(1-
δj(Nj))) if the last time point in one group is an actual event, and the one in the other group 
is censored, i.e. one survival curve is open, and the other one is closed; and τ = 
maxj(Xj(Nj)) if the last time points in both groups are actual events, i.e. both survival 
curves are closed at the right tails. Note, in the right hand side of equation, the tj+1 for the 
last element in the summation is defined as τ instead. (Lin and Xu 2009) 
 
The expected value of delta (E(∆)), can be estimated by: 
 
:`	a = ∑ b(c|
 [deBE( ( + deB2( (]}
1/2(6  , 
wheredeBE( = var( 6	f ), and deB2( = var((	f ).  
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The variance of delta, Var(a can be estimated as follows 
 !"# 	∆=∑ 	6  (	1 |
_ (c[deBE( ( + deB2( (] + ∑ 	6   	′6 ′|,′

′ (1-(c)*{g deBE( ( + deB2( (h deBE( ( ′ + deB2( ( ′]}
1/2 
where i≠i’ 
Given what’s above, the following test statistic proposed by Lin and Xu for the 
comparison of the survival curves between the two groups is 
 
∆* = 
∆01	∆f
i345# 	∆ 
 
∆* is asymptotically standard normal (Lin and Xu 2009).  The null hypothesis is rejected 
at a significance level α if ∆* >j60α, where  j60α is the point with cumulative probability 
(1-α) in a standard normal distribution. 
 
2.5. PROPOSED WEIGHTED LIN & XU’S TEST STATISTIC 
The proposed weighted test statistic is a variation of Lin and Xu’s test statistic 
that applies a different weight at the kK  failure time.  The purpose of adding this weight 
component to the new test statistic is to compare the power of the test to Lin and Xu’s 
original propose test statistic to see if a specific weight function is considered more 
powerful for all-purpose situations. The various tests that will be applied to our 
simulation are shown below along with their corresponding weight components. 
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TABLE 2.1 Test statistics whose weights were applied to Lin and Xu’s test statistic 
Test Statistic W(lm) 
Log rank 1 
Gehen  
Tarone-Ware i 
Peto W̃	 
MPeto 6 * W̃	 
 
 
Similar to the Gehen (i.e. Wilcoxon) test, the Tarone-Ware test statistic applies more 
weight to the early failure times by weighting the observed minus expected score at time 
 by the square root of the number at risk, i.  The Peto test weights the ith failure time 
by the survival estimate, W̃	, calculated overall groups combined. The survival estimate 
W̃	 is similar but not exactly equal to the Kaplna-Meier survival estimate. The MPeto 
weight takes the ratio of the number at risk at time ti divided by the number at risk at time 
ti plus 1 multiplied by the survival estimate, W̃	, calculated overall groups combined 
(Klein 1997). 
The observed absolute difference of the areas under the two survival curves with the 
applied weight is defined below. 
∆L= \ o	 p ]6	  (	]^_  = ∑ o	 p ]6	  (	]	6  |
  
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The expected value of the weighted delta can be estimated by: 
 
:`	∆L = ∑ o	 p b(c|
 [deBE( ( + deB2( (]}
1/2(6   
 
Furthermore, the estimated variance of the weighted delta can be estimated by 
 
 !"# 	∆L=∑ o	( p 	6  (	1 |
 (п[deBE( 	 + deB2( (] + ∑ 	6 ′|,′

 	′6  ′ (1-(
п
)*{g deBE( ( + deB2( (h deBE( (′ + deB2( (′]}1/2*o	2 
Where i≠i’ 
Therefore, we obtain a weighted test statistic given by 
 
∆w* = 
∆q01	∆qf
i345# 	∆q
 
∆L* is asymptotically standard normal (Lin and Xu, 2009).  The null hypothesis is 
rejected at a significance level α if ∆w* > j60α, where  j60α is the point with cumulative 
probability (1-α) in a standard normal distribution. 
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CHAPTER 3 
SIMULATION STUDY 
 
Lin and Xu (2009) conducted a simulation study to examine the statistical power 
of their proposed test statistic, ∆*, under a variety of situations. They claimed that ∆* was 
robust in the comparison of overall homogeneity of survival curves whether or not the 
underlying PH assumption was met. However, they did not investigate the weighted 
version of this test statistic.  Therefore, in our study, we performed a similar Monte Carlo 
simulation to compare the statistical power of Lin and Xu’s testing method, the new 
weighted version of their testing method, the log rank test, the Wilcoxon test, and the 
Kolmogorov-Smirnov test. 
 
3.1 SIMULATION DESIGN 
 As stated earlier, we consider the same three situations utilized by Lin and Xu 
(2009).  In Situation 1, we have two survival curves that intersect one another.  In 
Situation 2, the two survival curves are identical in the beginning, then separate as time 
goes on.  In Situation 3, the two survival curves have proportional hazard rates. Figure 
3.1 displays each situation by plotting the survival time versus the survival probability. 
Similar to Lin and Xu’s simulation study (2009), we conducted 1000 iterations in each 
simulation study and exhibited the statistical power of the log rank test, 
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Wilcoxon test, Kolmogorov-Smirnov test, Lin and Xu’s test (2009), and the proposed 
weighted test statistic.  Comparable to Lin and Xu (2009), the estimated statistical power 
was calculated as the proportion of 1000 repeated random samples where we reject the 
null hypothesis at the 0.05 significance level.  
 
       Situation 1                         Situation 2                                  Situation 3    
 
 
 
 
 
 
 
FIGURE 3.1.Three situations that are considered in the simulation study. 
 
For Situation 1, we considered the same situation as Lin and Xu (2009) in where 
the survival times in Group I follow an exponential distribution with mean of 6, and in 
Group II the survival times follow an exponential distribution with mean of 2.  Yet, if the 
survival time in Group II is greater than or equal to 1.5, then the survival time is 
simulated to follow an exponential distribution with mean of 40 (see Figure 3.1, Situation 
1).  Also akin to Lin and Xu’s (2009) study, we considered censoring to better evaluate 
the performance of the tests in Situation 1.  In the first situation we considered no 
censoring, while the second scenario we based censoring on a fixed period of follow-up.  
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If the survival time is greater than 12, then the observation was censored.  The censoring 
survival time for this situation plus each of the following situations were chosen based on 
Lin and Xu’s (2009) simulation study to keep the studies as comparable as possible with 
a censoring rate for group 1 and group 2 of about 14 percent and 19 percent, respectively.  
For Situation 2 (see Figure 3.1, Situation 2), both Groups I and II have survival 
times that follow an exponential distribution with mean of 4. However, if the survival 
time in Group II is greater than or equal to 4, then the survival time is simulated to follow 
an exponential distribution with a mean of 20.  Again, for better assessment of 
performance of the tests, the following censoring scenarios were considered.  For 
scenario 1, no censoring was considered, while for scenario 2 censoring was based on a 
fixed period of follow-up.  If the survival time is greater than 12, then the observation 
was censored.  The censoring rates for group 1 and group 2 are about 5 percent and 14 
percent, respectively. 
For Situation 3 (see Figure 3.1, Situation 3), Group I follows an exponential 
distribution with mean of 2, while Group II follows an exponential distribution with a 
mean of 5.  For better judgment of performance for each test, the following censoring 
scenarios were considered.  For scenario 1 no censoring was considered, while for 
scenario 2 censoring was based on a fixed period of follow-up.  If the survival time is 
greater than 10, then the observation was censored.  The censoring rate for group 1 and 
group 2 are about 1 percent and 14 percent, respectively. 
Not only are we interested in comparing the power of the test, we also want to 
investigate the estimation of the Type I error for each test statistic.  The Type I error is 
the probability of rejecting the null hypothesis given the null is true.  In terms of this 
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study, it is the probability that the survival curves are different when in actuality, they are 
the same.  We want this probability to be near the nominal value of 0.05.  Not only is it 
important to have a high power for the newly proposed test statistic, but we also want a 
small probability of falsely rejecting the null hypothesis.  The test can have high power, 
but with a high probability of false rejections, which would make for a poor testing 
procedure. 
To estimate the Type I error we created Situation 4 where we considered the same 
scenario as Lin and Xu (2009) where two random samples were generated independently 
from an exponential distribution with mean of 4. Again, for better judgment of 
performance, the following censoring scenarios were considered.  For scenario 1, no 
censoring was considered, while for scenario 2 censoring was based on a fixed period of 
follow-up.  If the survival time is greater than 10, then the observation was censored.  
According to Lin and Xu (2009), the censoring rate is approximately 8% in each of the 
two groups.  
Situation 5 is another simulation created to test the Type I error. We generated 
two random samples independently that follow an exponential distribution with mean of 
2. If the data point was greater than or equal to 1.5 then the data point was re-generated to 
follow an exponential distribution with mean of 6.  The same censoring scenarios were 
considered as the previous Type I error simulation.  According to Lin and Xu (2009), the 
censoring rate is approximately 9% in each of the two groups.    
The same sample sizes that were created in Lin and Xu’s study were replicated for 
our study. These vary from 20 to 100 in each group, representing equal and unequal 
sample sizes.  The following sample size combinations were used for each situation and 
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both censoring scenarios, (group1, group2): (20, 20), (40, 40), (50, 50), (60, 60), (80, 80), 
(100, 100), (20, 50), (50, 20), (50, 100), (100, 50). 
 For our study we are expecting to see several different outcomes.  While we 
believe that the new weights added to Lin and Xu’s test statistic will perform better, we 
expect different weights to work better for different situations.  For Situation 1 and 2, we 
believe that the Peto weight will perform the best because it is the most flexible among 
the weights we are testing.  We are expecting the Wilcoxon and Tarone-Ware weights 
will perform the worst for Situation 2 since we would want the weight to depend more on 
later failure times, where the Wilcoxon and Tarone-Ware weigh more on early failure 
times.  In Chapter 4 we will present the results of the power for each of the three 
situations, as well as, the Type I error estimations
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CHAPTER 4 
SIMULATION RESULTS 
 
In this chapter we present the results based on the simulation design that was presented in 
Chapter 3. Tables 4.1 – 4.6 show the results of the power of the four existing tests plus 
the four newly proposed weighted tests that were applied to each of the three situations. 
 
4.1. SIMULATION RESULTS 
 Tables 4.1 and 4.2 below show the power results for Situation 1 (see description, 
p. 27).  Based on previous research, the log rank test statistic is the least powerful in a 
situation where the survival curves overlap (Schoenfeld 1981).  This is apparent in Tables 
4.1 and 4.2 where the log rank test does not exceed a power 0.715, and an average power 
of 0.282, averaging across both censoring and non-censoring scenarios.  The Wilcoxon 
test also performed poorly for situation 1 for both censoring and non-censoring scenarios 
with a power not exceeding 0.303. As noted earlier, it is expected that the Kolmogorov-
Smirnov test to perform reasonably well in this situation.  However, in Tables 4.1 and 
4.2, we see that results for Lin & Xu’s test statistic for the non-censoring scenario 
performs considerably better than the Kolmogorov-Smirnov test.  These results are 
consistent with Lin and Xu’s simulation results (2009). 
  
 
TABLE 4.1 Power of the four test plus weighted tests in Situation 1 (without censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov Test 
Lin &Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.186 0.100 0.207 0.679 0.691 0.699 0.691 0.681 
(40, 40) 0.344 0.120 0.545 0.971 0.981 0.981 0.981 0.979 
(50, 50) 0.429 0.121 0.712 0.990 0.995 0.995 0.995 0.995 
(60, 60) 0.482 0.134 0.877 0.999 0.998 0.999 0.998 0.998 
(80, 80) 0.597 0.164 0.986 1 1 1 1 1 
(100, 100) 0.715 0.167 1 1 1 1 1 1 
 
        
(20,50) 0.110 0.049 0.318 0.973 0.948 0.967 0.948 0.945 
(50, 20) 0.396 0.180 0.491 0.747 0.781 0.800 0.781 0.772 
(50, 100) 0.376 0.091 0.875 1 1 1 1 1 
(100, 50) 0.662 0.211 0.978 0.999 1 1 1 1 
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TABLE 4.2 Power of the four test plus weighted tests in Situation 1 (with censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov Test 
Lin &Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.090 0.122 0.224 0.223 0.282 0.247 0.282 0.284 
(40, 40) 0.104 0.157 0.537 0.567 0.637 0.597 0.637 0.639 
(50, 50) 0.128 0.158 0.683 0.722 0.790 0.772 0.790 0.790 
(60, 60) 0.140 0.186 0.805 0.858 0.906 0.890 0.906 0.904 
(80, 80) 0.165 0.227 0.942 0.973 0.985 0.979 0.985 0.985 
(100, 100) 0.182 0.303 0.987 1 1 1 1 1 
 
        
(20,50) 0.046 0.074 0.370 0.430 0.465 0.447 0.465 0.467 
(50, 20) 0.153 0.191 0.385 0.291 0.358 0.327 0.358 0.358 
(50, 100) 0.098 0.142 0.852 0.921 0.955 0.939 0.955 0.955 
(100, 50) 0.231 0.266 0.884 0.924 0.958 0.951 0.958 0.958 
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For this study, we are concerned with how the weighted tests performed for Situation 1.  
Table 4.1 shows each of the four weighted tests perform just as well as Lin and Xu’s test 
statistic in terms of power.  However, there is no evidence of one weighted test 
performing better than the other. When considering censoring, Table 4.2 suggests that the 
tests using Gehen weight, Peto weight, and MPeto weight perform better than Lin and 
Xu’s test statistic, as well as, the log rank, Wilcoxon, and Kilmogorov-Smirnov test 
statistics. The Tarone weight test suggests that the power is similar to the power of Lin 
and Xu’s test, however, it not as powerful as the other three proposed weighted tests. The 
Tarone weight emphasizes weight on earlier failure times which does not apply for this 
situation.  Based on the results of the tables above, there does appear to be an influence 
on sample size  
 Tables 4.3 and 4.4 show the power results for Situation 2 (see description, p. 28).  
In this situation, the two survival curves are close in the beginning then separate as time 
goes on.  Based on previous research, it is expected that the log rank and Wilcoxon tests 
are less powerful than all the other tests.    In Table 4.3 and 4.4, the log rank test does not 
exceed a power of 0.1. In this particular situation, a logical weight emphasis should be 
considered on later failure times, thus, the Wilcoxon test performed poorly in this 
situation with a power that doesn’t surpass 0.32 and averages a power of 0.171 for both 
censoring and non-censoring scenarios. Table 4.3 and 4.4 suggests that the Kolmogorov-
Smirnov test performs better than log rank and Wilcoxon tests, however, it does not 
perform as well as Lin & Xu’s test statistic, which, like Situation 1, is consistent with Lin 
& Xu’s results (2009). 
  
 
TABLE 4.3 Power of the four test plus weighted tests in Situation 2 (without censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.052 0.094 0.075 0.116 0.113 0.115 0.113 0.118 
(40, 40) 0.050 0.148 0.181 0.331 0.257 0.278 0.257 0.245 
(50, 50) 0.041 0.183 0.220 0.502 0.337 0.425 0.337 0.329 
(60, 60) 0.052 0.241 0.305 0.651 0.457 0.596 0.457 0.443 
(80, 80) 0.061 0.294 0.409 0.864 0.569 0.794 0.569 0.561 
(100, 100) 0.055 0.334 0.481 0.936 0.725 0.883 0.725 0.716 
 
        
(20,50) 0.028 0.104 0.159 0.403 0.245 0.312 0.245 0.244 
(50, 20) 0.097 0.158 0.123 0.142 0.158 0.145 0.158 0.159 
(50, 100) 0.025 0.206 0.336 0.848 0.526 0.747 0.526 0.514 
(100, 50) 0.097 0.266 0.324 0.555 0.412 0.540 0.412 0.408 
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TABLE 4.4 Power of the four test plus weighted tests in Situation 2 (with censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.058 0.111 0.109 0.097 0.129 0.115 0.129 0.132 
(40, 40) 0.059 0.170 0.210 0.172 0.208 0.186 0.208 0.211 
(50, 50) 0.049 0.204 0.261 0.197 0.267 0.231 0.267 0.267 
(60, 60) 0.058 0.217 0.317 0.249 0.299 0.276 0.299 0.300 
(80, 80) 0.049 0.270 0.398 0.386 0.389 0.386 0.389 0.390 
(100, 100) 0.054 0.312 0.490 0.505 0.466 0.476 0.466 0.465 
 
        
(20,50) 0.034 0.107 0.174 0.134 0.169 0.153 0.169 0.170 
(50, 20) 0.092 0.143 0.121 0.120 0.153 0.133 0.153 0.155 
(50, 100) 0.046 0.233 0.384 0.339 0.357 0.345 0.357 0.356 
(100, 50) 0.084 0.252 0.310 0.278 0.315 0.398 0.315 0.317 
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When considering non-censoring, Table 4.3 shows that the power of Lin and Xu’s test 
statistic performs better than the four proposed weighted tests. The weighted Tarone test 
shows similar power results, however, for this situation, it would not make sense to add 
weight to earlier failure times when the survival curves are analogous.  When considering 
censoring, Table 4.4 suggests that the power using Kolmogorov-Smirnov, Lin &Xu, 
Gehen weight, Peto weight, Tarone weight, and MPeto weight perform similarly. 
However, the four weighted tests performing slightly better than Lin & Xu’s test statistic. 
Based on the results of the tables above, there does appear to be an influence on sample 
size.   
Tables 4.5 and 4.6 show the power results for Situation 3 (see description, p. 28).  
In this situation, the two survival curves are proportional to one another. Based on 
previous research, it is expected that the Log Rank Test would perform best in this type 
of scenario, while Wilcoxon and Kolmogorov-Smirnov would not perform nearly as well.  
We would also expect Lin and Xu’s test to perform as well as Log Rank in this situation 
when the survival curves are proportional.  In Table 4.5 and 4.6, the Log Rank test is 
consistently the most powerful with a power reaching 1 nearly every time. In this 
particular situation, a logical weight emphasis should be distributed evenly over the time 
(hence, why Log Rank is most powerful). Therefore, the Wilcoxon test was less powerful 
with an average power of 0.900 for both censoring and non-censoring scenarios.  Table 
4.5 and 4.6 suggests that the Kolmogorov-Smirnov test performs about the same as the 
Wilcoxon, with the log rank test surpassing both these tests.  However, Lin & Xu’s test 
statistic performs just as well as the Log Rank Test with powers consistently reaching 1, 
which is consistent with Lin and Xu’s study (2009). 
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Now that we have confirmed that our results are similar to Lin and Xu’s study 
(2009), we are concerned with the following weighted tests. When considering Situation 
3, it is evident in Tables 4.5 and 4.6, that there isn’t a particular weighted test that is 
consistently most powerful, nor are they better than Lin & Xu’s or Log Rank test. These 
results provide evidence that the four newly proposed weighted tests can be considered 
just as powerful as the Log Rank and Lin & Xu’s test when comparing survival curves 
that are proportional to one another.  Based on the results of the tables above, there does 
appear to be an influence of sample size.   
  
 
TABLE 4.5 Power of the four test plus weighted tests in Situation 3 (without censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.776 0.680 0.697 0.744 0.725 0.749 0.725 0.719 
(40, 40) 0.976 0.931 0.962 0.965 0.945 0.963 0.945 0.945 
(50, 50) 0.994 0.973 0.989 0.989 0.980 0.986 0.980 .979 
(60, 60) 0.998 0.988 0.994 0.995 0.990 0.993 0.990 0.990 
(80, 80) 0.999 0.998 0.999 0.999 1 1 1 1 
(100, 100) 1 1 1 0.999 1 1 1 1 
 
        
(20,50) 0.939 0.876 0.812 0.933 0.903 0.922 0.903 0.900 
(50, 20) 0.906 0.787 0.908 0.843 0.825 0.847 0.825 0.821 
(50, 100) 0.999 0.997 0.999 0.999 0.998 0.998 0.998 0.998 
(100, 50) 0.999 0.994 0.999 0.997 0.997 0.997 0.997 0.997 
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TABLE 4.6 Power of the four test plus weighted tests in Situation 3 (with censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.781 0.677 0.685 0.775 0.718 0.751 0.718 0.714 
(40, 40) 0.978 0.933 0.965 0.971 0.941 0.967 0.941 0.938 
(50, 50) 0.992 0.981 0.984 0.990 0.983 0.986 0.983 0.983 
(60, 60) 1 0.988 0.999 1 0.994 0.999 0.994 0.994 
(80, 80) 1 0.998 1 1 0.999 1 0.999 0.999 
(100, 100) 1 1 1 1 1 1 1 1 
 
        
(20,50) 0.923 0.866 0.818 0.932 0.891 0.918 0.891 0.890 
(50, 20) 0.904 0.803 0.913 0.871 0.851 0.874 0.851 0.852 
(50, 100) 1 0.998 1 1 0.997 1 0.997 0.997 
(100, 50) 1 0.992 1 0.999 0.993 0.998 0.993 0.993 
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When evaluating a test, in addition to the power of the test, appropriate control of the 
probability of a Type I error should also be considered.  Tables 4.7-4.10 present the 
results for Situations 4 and 5, where we look at the Type I Error estimation for each of 
the test statistics. 
 Tables 4.7 and 4.8 display the Type I Error results for situation 4 (see description, 
p. 29). These results are a bit inflated compared to the results given in Lin and Xu’s 
article (2009).  Therefore, we constructed single proportions 95% confidence interval to 
check if the nominal value of 0.05 is within the interval.  Based on these results, we are 
95% confident that the nominal value of the Type I Error lies between the values 0.036 
and 0.0635.   
 When considering Situation 4 without censoring, Table 4.7 shows that Lin & Xu’s 
test has a small amount of error (<0.05) along with log rank, Wilcoxon, and Kolmogorov-
Smirnov tests.  This is consistent with Lin & Xu’s results (2009).  Each of the weighted 
test statistics have an observed alpha level that lies within the interval of 0.036 and 
0.0635.  The results show that the eight tests have similar Type I error in this situation 
and the Type I error of the newly weighted testing method is controlled at the specified 
confidence interval (0.036, 0.0635)   
When considering Situation 4 with censoring, Table 4.8 shows that each of the 
existing test statistics have a relatively small amount of error which all lie within the 
interval of 0.036 and 0.0635.  Each of the weighted test statistics also show similar results 
of smaller error amounts that lie within this interval.  The simulation results are a bit 
inflated compared to Lin & Xu’s results (2009). The results show that the eight tests have 
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similar Type I error in this situation and the Type I error of the newly weighted testing 
method is controlled based on the 95% confident interval constructed for this situation.
  
 
 
TABLE 4.7 Type I Error estimation of the four test plus weighted tests in Situation 4 (without censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.058 0.052 0.037 0.051 0.062 0.053 0.062 0.060 
(40, 40) 0.051 0.055 0.049 0.037 0.056 0.047 0.056 0.057 
(50, 50) 0.050 0.045 0.040 0.035 0.047 0.041 0.047 0.047 
(60, 60) 0.061 0.044 0.044 0.038 0.047 0.045 0.047 0.047 
(80, 80) 0.040 0.040 0.032 0.023 0.041 0.031 0.041 0.043 
(100, 100) 0.048 0.046 0.041 0.030 0.046 0.039 0.046 0.046 
 
        
(20,50) 0.058 0.054 0.046 0.045 0.057 0.052 0.057 0.057 
(50, 20) 0.059 0.054 0.052 0.052 0.066 0.057 0.066 0.067 
(50, 100) 0.060 0.057 0.055 0.047 0.055 0.047 0.055 0.055 
(100, 50) 0.064 0.052 0.055 0.050 0.048 0.049 0.048 0.048 
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TABLE 4.8 Type I Error estimation of the four test plus weighted tests in Situation 4 (with censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *BOLD INDICATES OUTSIDE OF CONFIDENCE INTERVAL  
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.054 0.057 0.038 0.060 0.062 0.061 0.062 0.063 
(40, 40) 0.045 0.050 0.042 0.057 0.056 0.059 0.056 0.056 
(50, 50) 0.056 0.050 0.040 0.054 0.051 0.049 0.051 0.051 
(60, 60) 0.061 0.055 0.056 0.069 0.059 0.061 0.059 0.059 
(80, 80) 0.063 0.053 0.060 0.066 0.055 0.056 0.055 0.055 
(100, 100) 0.051 0.057 0.054 0.062 0.056 0.062 0.056 0.056 
 
        
(20,50) 0.051 0.052 0.044 0.053 0.057 0.054 0.057 0.057 
(50, 20) 0.067 0.059 0.059 0.072 0.070 0.069 0.070 0.070 
(50, 100) 0.054 0.041 0.043 0.059 0.046 0.053 0.046 0.045 
(100, 50) 0.055 0.057 0.056 0.067 0.062 0.058 0.062 0.062 
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Tables 4.9 and 4.10 display the Type I error estimates for Situation 5 (see description, p. 
29).  When considering Situation 5 without censoring, Table 4.9 shows that Lin & Xu’s 
test has a small amount of error along with log rank, Wilcoxon, and Kolmogorov-
Smirnov test statistics, based on the 95% confidence interval (0.036, 0.0635).  This is 
consistent with Lin & Xu’s results (2009).  The four weighted tests also show that the 
Type I error results mainly fall within the interval of 0.036 and 0.0635.  Therefore, the 
weighted tests claim to have small amount of error, as well as, the four pre-existing tests. 
When considering Situation 5 with censoring, Table 4.10 shows that the three pre-
existing test statistics have relatively small Type I error based on our 95% confidence 
interval. Lin & Xu’s and the four newly proposed weighted test statistics have a few more 
results that are above our liking for Type I error probability. The Type I error results 
seem to be inflated compared to Lin & Xu’s results (2009). The results show that the log 
rank, Wilcoxon, and Kolmogorov-Smirnov tests demonstrate similar Type I error in this 
situation. Also based on the 95% confidence interval, we conclude that the four weighted 
tests have a better type I error and Lin and Xu’s test by consistently having smaller 
amounts of error.  There are a few examples where the Type I error falls outside of our 
interval, but the majority of the results fall within the confident interval of 0.036 and 
0.0635.
  
 
TABLE 4.9 Type I Error estimation of the four test plus weighted tests in Situation 5 (without censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *BOLD INDICATES OUTSIDE OF CONFIDENCE INTERVAL  
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.060 0.047 0.037 0.068 0.060 0.065 0.060 0.061 
(40, 40) 0.056 0.047 0.043 0.051 0.055 0.055 0.055 0.056 
(50, 50) 0.056 0.052 0.046 0.047 0.055 0.058 0.055 0.057 
(60, 60) 0.055 0.047 0.042 0.047 0.049 0.046 0.049 0.049 
(80, 80) 0.044 0.043 0.034 0.038 0.043 0.042 0.043 0.043 
(100, 100) 0.052 0.053 0.057 0.048 0.041 0.039 0.041 0.041 
 
        
(20,50) 0.052 0.060 0.00 0.068 0.067 0.064 0.067 0.069 
(50, 20) 0.058 0.062 0.044 0.069 0.067 0.066 0.067 0.70 
(50, 100) 0.052 0.048 0.042 0.045 0.051 0.042 0.051 0.051 
(100, 50) 0.054 0.049 0.044 0.048 0.047 0.054 0.047 0.048 
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TABLE 4.10 Type I Error estimation of the four test plus weighted tests in Situation 5 (with censoring) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *BOLD INDICATES OUTSIDE OF CONFIDENCE INTERVAL  
Sample 
size 
Log-
Rank 
Test 
Wilcoxon 
Test 
Kolmogorov-
Smirnov 
Test 
Lin 
&Xu 
Log-
Rank 
Weight 
Gehen 
Weight 
Tarone 
Weight 
Peto 
Weight 
MPeto 
(20,20) 0.054 0.052 0.037 0.064 0.059 0.067 0.059 0.060 
(40, 40) 0.052 0.049 0.047 0.070 0.060 0.067 0.060 0.057 
(50, 50) 0.052 0.048 0.036 0.067 0.057 0.056 0.057 0.057 
(60, 60) 0.048 0.038 0.043 0.063 0.050 0.058 0.050 0.051 
(80, 80) 0.050 0.057 0.051 0.078 0.057 0.068 0.057 0.057 
(100, 100) 0.047 0.050 0.047 0.073 0.054 0.063 0.054 0.053 
 
        
(20,50) 0.055 0.061 0.046 0.093 0.073 0.090 0.073 0.075 
(50, 20) 0.059 0.050 0.048 0.085 0.068 0.083 0.068 0.068 
(50, 100) 0.047 0.048 0.046 0.075 0.059 0.069 0.059 0.060 
(100, 50) 0.044 0.039 0.034 0.060 0.049 0.053 0.049 0.049 
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4.2. CONCLUSION AND DISCUSSION 
 
 In Conclusion, based on the results of the Type I error estimates in Tables 4.7-
4.10, we suggest that the four weighted Lin and Xu’s test statistics perform just as well, if 
not slightly better, than Lin and Xu’s original test statistic and the three other pre-existing 
tests. Not only were they slightly more powerful than Lin and Xu’s test, but with our 95% 
confidence interval, it was also evident that these weighted tests had proper Type I error 
values as well.  Also, in tables 4.1-4.10, the Gehen and Peto weight had the same power 
and Type I error results for each situation.  This may be due to the censoring rate of the 
simulation data.  If there is an increase in censoring, that may affect the results of the 
power and Type I error. We further conclude that the larger the sample size, the more 
powerful the test, which is to be expected.  
In the end we believe that the weighted test statistics  is at least comparable to  the Log 
rank, Wilcoxon, Kolmogorov-Smirnov, and Lin & Xu’s test statistics, sometime is better.  
However, we would only suggest using these weighted tests if it was necessary with the 
data at hand.  If it doesn’t make sense to apply these weight components, then we suggest 
to simply use Lin and Xu’s original test statistic, however, there adding the weight 
component wouldn’t harm the analysis.  
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CHAPTER 5 
 
REAL DATA RESULTS 
 
5.1. REAL DATA EXAMPLE  
For illustration, we apply our new method to the Leukemia data introduced in Chapter 1, 
Section 1.3.  First, we consider the comparison of the treatment (Group 1) and placebo 
(Group 2) subjects. We consider the null hypothesis that the leukemia patient groups have 
the same survival distribution against the alternative that the survival distributions are 
different.  Referring back to Figure 1.2, we see that the two treatment groups appear to be 
proportional to each other because the plot shows that their survival curves are not 
intersecting.  Similarly, Figure 1.2 plots the logarithm cumulative hazard function versus 
log of survival time graph and result in proportional curves as well. 
 Based on the simulation results in Chapter 3 for proportional curves, we expect 
Lin & Xu’s and the newly weighted test statistics to perform just as well as the log rank 
test.  Table 5.1 shows the p-value of each test statistic when stratifying by group.
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TABLE 5.1.P-value of each test statistic when comparing survival curves stratified by 
group 
 
 
Test Statistic P-Value 
Log Rank 0.00004 
Wilcoxon 0.00014 
Kolmogorov-
Smirnov 
0.00050 
Lin & Xu 0.00000 
Gehen 0.00000 
Tarone 0.00000 
Peto 0.00000 
Mpeto 0.00000 
 
From these p-values for each test statistic, we conclude, at the 0.05 significance level, 
that patients who receive the 6-Mercaptopurine treatment have a longer survival rate than 
the patients in the placebo group. 
For the second example, instead of stratifying by group, we stratify by gender.  
We consider the null hypothesis that the leukemia patients adjusted by gender have the 
same survival distribution against the alternative that the survival distributions are 
different.  Referring back to Figure 1.3, this plot displays that these two hazards are not 
proportional to each other.  Similarly, Figure 1.4 displays the cumulative hazard function 
versus log of survival time graph and result in intersecting hazards which as a result 
claim that the PH assumption not being satisfied. As a reminder, we stated earlier that 
when stratifying by gender, it appears that male patients begin with a larger survival 
probability, but over time women appear to have a higher survival probability.  
Therefore, it is more difficult to determine if there is in fact a difference in survival 
probability. We apply our new testing method by using Lin and Xu’s method along with 
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the newly proposed weighted test statistics to analyze this hypothesis.  Based on the 
simulation results in Chapter 4 for non-proportional curves, we obtain less accurate 
estimates while adjusting for gender for the log rank test and Wilcoxon test statistic.  We 
expect the weighted component test statistics to yield the most accurate results based on 
this situation. However, while these weight components will still have accurate results, 
these weights do not necessarily apply to this specific dataset, therefore, it would make 
most sense to apply Lin and Xu’s original test statistic. Table 5.2 shows the p-value of 
each test statistic when stratifying by gender. 
 
TABLE 5.2. P-value of each test statistic when comparing survival curves stratified by 
gender 
 
 
Test Statistic P-Value 
Log Rank 0.3872 
Wilcoxon 0.8200 
Kolmogorov-
Smirnov 
0.2515 
Lin & Xu 0.0158 
Gehen 0.0122 
Tarone 0.0146 
Peto 0.0129 
Mpeto 0.0128 
 
Based on the p-values presented in Table 5.2, the log rank, Wilcoxon, and Kolmogorov-
Smirnov test statistics conclude that there is no difference detected in survival curves 
when stratifying by gender.  However, we know that these tests lack power, therefore, 
may not represent accurate results. Lin and Xu’s test statistic, as well as, the four 
weighted test statistics, lead us to conclude that there is a difference in survival curves 
when stratifying by gender.  Based on our simulation study, we know these test statistics 
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have high power and significant Type I error values.  Therefore, based on Figures 1.3 and 
1.4, as well as, the p-value presented in Table 5.2 for Lin &Xu’s test statistic, we 
conclude that there is a significant difference in survival between male and female 
leukemia patients, with a p-values for Lin and Xu’s test and the four weight components 
tests being less and 0.05. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK 
In this thesis, we investigated the efficiency of adding a weight component to a test 
statistic based on the method proposed by Lin and Xu (2009) that would be effective for 
all-purpose situations when comparing survival curves that may or may not be 
proportional.  The difference between this new method compared to existing test 
statistics, is that this test takes into consideration the length of time intervals to better 
capture the differences.  Our proposed method was to apply a different weight at the 
kKfailure time. In this study, we compared the power of the weighted test statistics to Lin 
and Xu (2009) original testing method.  We also tested the accuracy of these weighted 
test statistics by analyzing the Type I error estimations. 
 After we investigated the power and Type I error of each weighted test statistic, 
we conclude that each weighted approach had slightly better results when compared to 
the power of Lin and Xu’s test statistic  in most of cases.  There was not a specific weight 
component that was consistently better than the other for all three of our situations 
presented throughout the thesis. Therefore, we conclude that the best test statistic to use 
when comparing survival distributions for all-purposes is Lin and Xu’s original testing 
method, or use the applied weight components if necessary.  Adding the weight 
components to Lin and Xu’s test statistic is not only very powerful in all circumstances, 
the Type I error estimation proves to be efficient as well. 
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 For future work, we suggest investigating the Flemington-Harrington weight 
component. The Flemington-Harrington test uses the Kaplan-Meier survival estimate 
over all groups to calculate its weights for the ith failure time.  This weight component is 
appealing because it allows the most flexibility in terms of the choice of weights because 
the user can provide specific values to the weight component.  For example, this weight 
component can apply more weight on later failure times rather than early failure times.     
There were also a few limitations to our simulation study. For example, we only 
generated data from exponential distributions.  For future work, we can generate data 
from a variety of distributions, which would capture different shapes of the hazard risk 
functions.  We would also want to consider different censoring rates to see how that 
would directly affect the results of the power and Type I error values.  For example, if 
there was an increase in censoring would that increase or decrease the power and Type I 
error values of the weight components. 
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